Sandoz – Recall of enoxaparin injection

- On December 2, 2021, Sandoz announced a voluntary, consumer-level recall of one lot of enoxaparin 40 mg/0.4 mL single-dose syringes because a portion of the recalled lot experienced a temperature excursion during shipment.

- The recalled lot was distributed in the months of September and October 2021.

Product Description	NDC	Lot # (Expiration Date)
Enoxaparin sodium injection, 40 mg/0.4 mL	00781-3246-64	SAB06761A (4/2023)

- Enoxaparin injection is indicated for the prophylaxis and treatment of deep vein thrombosis, prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction (MI), and for the treatment of acute ST-segment elevation MI.

- Per Sandoz, exposure to higher temperatures may have significantly impacted the recalled product's effectiveness and thus there may be reasonable probability of risk for patients with health conditions that the product is intended to treat.

    — Such patients could be at risk for blood clots blocking blood vessels, an artery, or traveling to other tissues or organs causing pain, swelling, stroke, clots to the lung or death as a result of the underlying condition.

- To date, Sandoz has not received any reports of adverse events or injuries related to this recall.

- Patients should contact their health care provider if they have experienced any problems that may be related to using the recalled enoxaparin.

- Patients who have the recalled enoxaparin injection should stop taking the recalled product, immediately consult with their health care provider to attain another prescription, and return the product where originally purchased.

- Contact Sandoz by phone at **1-800-525-8747** or by email at **qa.drugsafety@sandoz.com** for more information about the recall.